Which stock wins in a matchup between an up-and-coming Canadian cannabis producer and a U.S. hemp CBD leader?
Growth in the demand for telehealth services, combined with a great strategy, should help this stock win over the next decade.
Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.
Disappointed with its latest quarterly results? The cannabis producer's CEO identified plenty of good news that should be on the way.
Weak quarterly results weighed on the cannabis extraction company's shares.
Massive growth is coming for the global cannabis market, according to Tilray's top execs. And they think Tilray is poised to be a big winner.
The Canadian cannabis producer delivered sizzling year-over-year revenue growth in its third quarter thanks to adult-use sales. However, its limited production capacity remained an issue.
This biotech stock is super-hot right now thanks to the early success for its CBD drug. But here's what to keep your eyes on to see if GW will stay hot.
This Pot Powerhouse Made More Than Cronos and Tilray Combined Last Quarter -- and You've Probably Never Heard of It
This under-the-radar pot stock could soon be on plenty of investors' radar screens.
New blockbusters could be on the way for five drugmakers.
A new patent is generating excitement among investors for this clinical-stage biotech stock.
While many are hating on Cronos Group, one analyst thinks the company is poised to be a big winner in the U.S.
This cannabis stock stands out from all the rest. But is it really the only one worth buying right now?
Good news for the company's G6 CGM system translated to a nice gain.
The Canadian cannabis giant's pending deal with its majority owner is excellent news for its other shareholders.
Which stock wins in a battle between these two big drugmakers?
The future for this Canadian marijuana producer looks pretty bright.
These stocks are down but definitely not out.
Illumina, Teladoc Health, and Vertex Pharmaceuticals enjoy strong competitive advantages and great growth opportunities.
Some marijuana stocks are worth a serious look. These aren't.